Bristol-Myers Squibb is using an acquisition that could be worth more than $1 billion and a separate collaboration agreement to continue its push into developing cancer treatments that use a patient’s immune system to attack the disease. The New York drugmaker said Monday that it will buy the privately held biotechnology company Flexus for $800 million up front and another $450 million in possible milestone payments.

Click here to read original article